Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVPRapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-D - Serum - Document - PDFSEARCH.IO

First Page	Meta Content
	Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVPRapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-D Add to Reading List Document Date: 2018-04-10 18:00:06 Open Document File Size: 1,35 MB Share Result on Facebook

Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with SVPRapamycin Enables Sustained Reduction of Serum Uric Acid Levels by Mitigating Formation of Anti-DAdd to Reading List